The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension, and Mortality in Sickle Cell Disease
Open accessAbstract
CONTEXT: Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of l-arginine, the substrate for nitric oxide synthesis. We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes. OBJECTIVE: To explore the role of arginase in sickle cell disease pathogenesis, pulmonary hypertension, and mortality. DESIGN: Plasma amino acid levels, plasma and erythrocyte arginase activities, and pulmonary hypertension status as measured by Doppler echocardiogram were prospectively obtained in outpatients with sickle cell disease. Patients were followed up for survival up to 49 months. SETTING: Urban tertiary care center and community clinics in the United States between February 2001 and March 2005. PARTICIPANTS: Two hundred twenty-eight patients with sickle cell disease, aged 18 to 74 years, and 36 control participants. MAIN OUTCOME MEASURES: Plasma amino acid levels, plasma and erythrocyte arginase activities, diagnosis of pulmonary hypertension, and mortality. RESULTS: Plasma arginase activity was significantly elevated in patients with sickle cell disease, with highest activity found in patients with secondary pulmonary hypertension. Arginase activity correlated with the arginine-ornithine ratio, and lower ratios were associated with greater severity of pulmonary hypertension and with mortality in this population (risk ratio, 2.5; 95% confidence interval [CI], 1.2-5.2; P = .006). Global arginine bioavailability, characterized by the ratio of arginine to ornithine plus citrulline, was also strongly associated with mortality (risk ratio, 3.6; 95% CI, 1.5-8.3; P<.001). Increased plasma arginase activity was correlated with increased intravascular hemolytic rate and, to a lesser extent, with markers of inflammation and soluble adhesion molecule levels. CONCLUSIONS: These data support a novel mechanism of disease in which hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide. The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied Survival Analysis: Regression Modeling of Time-to-Event Data
Hosmer, D. W., Lemeshow, S. A., & May, S. J. (2008) · Cited by 3,030
Arginine metabolism: nitric oxide and beyond
WU, G., & MORRIS, S. M. (1998) · Biochemical Journal · doi:10.1042/bj3360001 · Cited by 2,811
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
R EGULATION OF E NZYMES OF THE U REA C YCLE AND A RGININE M ETABOLISM
Morris, S. M. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110801.140547 · Cited by 725
Xia, Y., Dawson, V. L., Dawson, T. M., Snyder, S. H., & Zweier, J. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6770 · Cited by 718
Chung, K. F., & Barnes, P. J. (1999) · Thorax · doi:10.1136/thx.54.9.825 · Cited by 638
Circulating Activated Endothelial Cells in Sickle Cell Anemia
Solovey, A., Lin, Y., Browne, P., Choong, S., Wayner, E., & Hebbel, R. P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711273372203 · Cited by 628
Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase
Heinzel, B., John, M., Klatt, P., Böhme, E., & Mayer, B. (1992) · Biochemical Journal · doi:10.1042/bj2810627 · Cited by 530
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1510865 · Cited by 1,488
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Arginine metabolism and nutrition in growth, health and disease
Wu, G., Bazer, F. W., Davis, T. A., Kim, S. W., Li, P., Marc Rhoads, J., Carey Satterfield, M., Smith, S. B., Spencer, T. E., & Yin, Y. (2009) · Amino Acids · doi:10.1007/s00726-008-0210-y · Cited by 1,362
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Self-citationPathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Intravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Kato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661
“The second involves the release of erythrocyte arginase, which converts plasma L-arginine into ornithine, resulting in depletion of plasma L-arginine, the required substrate for nitric oxide production by nitric oxide synthase, with associated pulmonary hypertension.(19;20;37) LDH also correlates with endothelial deri…”
BackgroundMethodInfluentialSelf-citationPiel, F. B., Steinberg, M., & Rees, D. C. (2016) · Spiral (Imperial College London) · doi:10.1056/nejmc1706325#sa6 · Cited by 659
Arginine Metabolism: Boundaries of Our Knowledge
Morris, S. M. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.6.1602s · Cited by 637
Strategies to increase nitric oxide signalling in cardiovascular disease
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4623 · Cited by 576
ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION
Durante, W., Johnson, F. K., & Johnson, R. A. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04638.x · Cited by 577
Cooper, C., Booth, A., Varley-Campbell, J., Britten, N., & Garside, R. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0545-3 · Cited by 561
Donadee, C., Raat, N. J. H., Kanias, T., Tejero, J., Lee, J. S., Kelley, E. E., Zhao, X., Liu, C., Reynolds, H., Azarov, I., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.008698 · Cited by 572
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
Tejero, J., Shiva, S., & Gladwin, M. T. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2017 · Cited by 541
Systematic review automation technologies
Tsafnat, G., Glasziou, P., Choong, M. K., Dunn, A., Galgani, F., & Coiera, E. (2014) · Systematic Reviews · doi:10.1186/2046-4053-3-74 · Cited by 472
Pulmonary Complications of Sickle Cell Disease
Gladwin, M. T., & Vichinsky, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0804411 · Cited by 470
Self-citationVoskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
“3) Reticulocyte, % 10 (1-40) 6* (1-23) 7* (1-35) 6* (1-18) Bilirubin, mg/dL 1.”
Priapism: Pathogenesis, Epidemiology, and Management
Broderick, G. A., Kadioglu, A., Bivalacqua, T. J., Ghanem, H., Nehra, A., & Shamloul, R. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01625.x · Cited by 400
Popovic, P. J., Zeh, H. J., & Ochoa, J. B. (2007) · The Journal of Nutrition · doi:10.1093/jn/137.6.1681s · Cited by 391
Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity
Romero, M. J., Platt, D. H., Tawfik, H. E., Labazi, M., El-Remessy, A. B., Bartoli, M., Caldwell, R. B., & Caldwell, R. W. (2008) · Circulation Research · doi:10.1161/circresaha.107.155028 · Cited by 386
Villagra, J., Shiva, S., Hunter, L. A., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2007) · Blood · doi:10.1182/blood-2006-12-061697 · Cited by 384
“In this model, reduced nitric oxide bioavailability and endothelial dysfunction results in the clinical development of pulmonary hypertension.(11;28;44;45) Increased platelet activation is another well described consequence of endothelial dysfunction and decreased NO bioavailability.”
BackgroundArginine-dependent immune responses
Martí i Líndez, A.-A., & Reith, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03828-4 · Cited by 354
Kato, G. J., Hebbel, R. P., Steinberg, M. H., & Gladwin, M. T. (2009) · American Journal of Hematology · doi:10.1002/ajh.21475 · Cited by 349
Pernow, J., & Jung, C. (2013) · Cardiovascular Research · doi:10.1093/cvr/cvt036 · Cited by 310
Iron-Overload Cardiomyopathy: Pathophysiology, Diagnosis, and Treatment
Murphy, C. J., & Oudit, G. Y. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.05.009 · Cited by 308
Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans
Wu, G., Meininger, C. J., McNeal, C. J., Bazer, F. W., & Rhoads, J. M. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-74180-8_10 · Cited by 301
Yeo, T. W., Lampah, D. A., Gitawati, R., Tjitra, E., Kenangalem, E., McNeil, Y. R., Darcy, C. J., Granger, D. L., Weinberg, J. B., Lopansri, B. K., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070819 · Cited by 299
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298
“Elevated arginase activity, with the resultant decrease in arginine/ornithine ratio, is associated with elevated pulmonary artery pressures (Gladwin et al, 2004; Morris et al, 2005).”
Host-Parasite Interactions Revealed by Plasmodium falciparum Metabolomics
Olszewski, K. L., Morrisey, J. M., Wilinski, D., Burns, J. M., Vaidya, A. B., Rabinowitz, J. D., & Llinás, M. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.01.004 · Cited by 289
Cardiovascular Abnormalities in Sickle Cell Disease
Gladwin, M. T., & Sachdev, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.10.900 · Cited by 276
Storage lesion: role of red blood cell breakdown
Kim‐Shapiro, D. B., Lee, J., & Gladwin, M. T. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03100.x · Cited by 271
Anthi, A., Machado, R. F., Jison, M. L., Taveira-DaSilva, A. M., Rubin, L. J., Hunter, L., Hunter, C. J., Coles, W., Nichols, J., Avila, N. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200610-1498oc · Cited by 270
Hsu, L. L., Champion, H. C., Campbell-Lee, S. A., Bivalacqua, T. J., Manci, E. A., Diwan, B. A., Schimel, D. M., Cochard, A. E., Wang, X., Schechter, A. N., et al. (2007) · Blood · doi:10.1182/blood-2006-08-039438 · Cited by 263
Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria
Gramaglia, I., Sobolewski, P., Meays, D., Contreras, R., Nolan, J. P., Frangos, J. A., Intaglietta, M., & van der Heyde, H. C. (2006) · Nature Medicine · doi:10.1038/nm1499 · Cited by 215
N-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease
Machado, R. F., Anthi, A., Steinberg, M. H., Bonds, D., Sachdev, V., Kato, G. J., Taveira-DaSilva, A. M., Ballas, S. K., Blackwelder, W., Xu, X., et al. (2006) · JAMA · doi:10.1001/jama.296.3.310 · Cited by 197
“Blood urea nitrogen, mg/dL 227 8 (6-11) 104 7 (6-10) .”
Cardiovascular complications and risk of death in sickle-cell disease
Gladwin, M. T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00647-4 · Cited by 164
Sachdev, V., Kato, G. J., Gibbs, J. S. R., Barst, R. J., Machado, R. F., Nouraie, M., Hassell, K. L., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.032920 · Cited by 147
Self-citationCerebrovascular disease associated with sickle cell pulmonary hypertension
Kato, G. J., Hsieh, M., Machado, R., Taylor, J., Little, J., Butman, J. A., Lehky, T., Tisdale, J., & Gladwin, M. T. (2006) · American Journal of Hematology · doi:10.1002/ajh.20642 · Cited by 100
“LDH is also a marker for the release of red cell arginase, which depletes the plasma of L-arginine, the substrate required for nitric oxide production [21,22].”
BackgroundGladwin, M. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29807 · Cited by 85
Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology
Bakeer, N., James, J., Roy, S., Wansapura, J., Shanmukhappa, S. K., Lorenz, J. N., Osinska, H., Backer, K., Huby, A.-C., Shrestha, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600311113 · Cited by 79
Cerebrovascular reserve capacity is impaired in patients with sickle cell disease
Nur, E., Kim, Y.-S., Truijen, J., van Beers, E. J., Davis, S. C. A. T., Brandjes, D. P., Biemond, B. J., & van Lieshout, J. J. (2009) · Blood · doi:10.1182/blood-2009-05-223859 · Cited by 79
Haematological determinants of cardiac involvement in adults with sickle cell disease
Damy, T., Bodez, D., Habibi, A., Guellich, A., Rappeneau, S., Inamo, J., Guendouz, S., Gellen-Dautremer, J., Pissard, S., Loric, S., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv555 · Cited by 65
Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study
Mack, A. K., McGowan II, V. R., Tremonti, C. K., Ackah, D., Barnett, C., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07259.x · Cited by 64
Self-citationCaughey, M. C., Poole, C., Ataga, K. I., & Hinderliter, A. L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13447 · Cited by 41
Blood, A. B., Schroeder, H. J., Terry, M. H., Merrill-Henry, J., Bragg, S. L., Vrancken, K., Liu, T., Herring, J. L., Sowers, L. C., Wilson, S. M., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.001073 · Cited by 36
Dynamic Cerebral Autoregulation in Homozygous Sickle Cell Disease
Kim, Y.-S., Nur, E., van Beers, E. J., Truijen, J., Davis, S. C. A. T., Biemond, B. J., & van Lieshout, J. J. (2009) · Stroke · doi:10.1161/strokeaha.108.531996 · Cited by 34
Cysteine–iron promotes arginase activity by driving the Fenton reaction
Iyamu, E. W., Perdew, H., & Woods, G. M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.102 · Cited by 26
Therapeutics Targeting of Dysregulated Redox Equilibrium and Endothelial Dysfunction
Risbano, M. G., & Gladwin, M. T. (2013) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-662-45805-1_13 · Cited by 32
Metadata
- Authors
- Morris, C. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-07-06
- Volume
- 294
- Issue
- 1
- Pages
- 81
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2049292864
- Cited by
- 763
- References
- 67
- FWCI
- 19.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.